<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78633</article-id><article-id pub-id-type="doi">10.7554/eLife.78633</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-274766"><name><surname>Zhang</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-274767"><name><surname>Han</surname><given-names>Zi Bo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-274768"><name><surname>Liang</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-274769"><name><surname>Zhang</surname><given-names>Xue Feng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-274770"><name><surname>Jin</surname><given-names>Yu Qin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-274771"><name><surname>Du</surname><given-names>Li Fang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-274772"><name><surname>Shao</surname><given-names>Shuai</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-274773"><name><surname>Wang</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-274774"><name><surname>Hou</surname><given-names>Jun Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-274775"><name><surname>Xu</surname><given-names>Ke</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-289550"><name><surname>Lei</surname><given-names>Wenwen</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-274776"><name><surname>Lei</surname><given-names>Ze Hua</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-274777"><name><surname>Liu</surname><given-names>Zhao Ming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-274778"><name><surname>Zhang</surname><given-names>Jin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" id="author-274779"><name><surname>Hou</surname><given-names>Ya Nan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf14"/></contrib><contrib contrib-type="author" id="author-274780"><name><surname>Liu</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf15"/></contrib><contrib contrib-type="author" id="author-274781"><name><surname>Shen</surname><given-names>Fu Jie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf16"/></contrib><contrib contrib-type="author" id="author-274782"><name><surname>Wu</surname><given-names>Jin Juan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-274783"><name><surname>Zheng</surname><given-names>Xiang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-274784"><name><surname>Li</surname><given-names>Xin Yu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-274785"><name><surname>Li</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-274786"><name><surname>Huang</surname><given-names>Wei Jin</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-274787"><name><surname>Wu</surname><given-names>Gui Zhen</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-274788"><name><surname>Su</surname><given-names>Ji Guo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="fn" rid="conf17"/></contrib><contrib contrib-type="author" corresp="yes" id="author-273295"><name><surname>Li</surname><given-names>Qi Ming</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8284-7106</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor4">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf18"/></contrib><aff id="aff1"><institution content-type="dept">The Sixth Laboratory</institution>, <institution>National Vaccine and Serum Institute</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><institution>Beijing Institute of Biological Products Company Limited</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff><aff id="aff3"><institution content-type="dept">National Institute for Viral Disease Control and Prevention</institution>, <institution>Chinese Center For Disease Control and Prevention</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff><aff id="aff4"><institution>National Institutes for Food and Drug Control</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-33388"><name><surname>Sigal</surname><given-names>Alex</given-names></name><role>Reviewing editor</role><aff><institution>University of KwaZulu-Natal</institution>, <country>South Africa</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>huangweijin@nifdc.org.cn</email> (WH);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>wugz@ivdc.chinacdc.cn</email> (GW);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>jiguosu@hotmail.com</email> (JS);</corresp><corresp id="cor4"><label>*</label>For correspondence: <email>liqiming189@163.com</email> (QL);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>08</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e78633</elocation-id><history><date date-type="received"><day>14</day><month>03</month><year>2022</year></date><date date-type="accepted"><day>22</day><month>08</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Zhang et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Zhang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-78633-v1.pdf"/><abstract><p>Large-scale populations in the world have been vaccinated with COVID-19 vaccines, however, breakthrough infections of SARS-CoV-2 are still growing rapidly due to the emergence of immune-evasive variants, especially Omicron. It is urgent to develop effective broad-spectrum vaccines to better control the pandemic of these variants. Here, we present a mosaic-type trimeric form of spike receptor-binding domain (mos-tri-RBD) as a broad-spectrum vaccine candidate, which carries the key mutations from Omicron and other circulating variants. Tests in rats showed that the designed mos-tri-RBD, whether used alone or as a booster shot, elicited potent cross-neutralizing antibodies against not only Omicron but also other immune-evasive variants. Neutralizing antibody ID50 titers induced by mos-tri-RBD were substantially higher than those elicited by homo-tri-RBD (containing homologous RBDs from prototype strain) or the BIBP inactivated COVID-19 vaccine (BBIBP-CorV). Our study indicates that mos-tri-RBD is highly immunogenic, which may serve as a broad-spectrum vaccine candidate in combating SARS-CoV-2 variants including Omicron.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>National Vaccine and Serum Institute</institution></institution-wrap></funding-source><award-id>KTZC1900026C</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Jing</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>National Vaccine and Serum Institute</institution></institution-wrap></funding-source><award-id>KTZC1900026C</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Qi Ming</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Jing Zhang, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf3"><p>Zi Bo Han, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf4"><p>Yu Liang, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf5"><p>Xue Feng Zhang, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf6"><p>Yu Qin Jin, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf7"><p>Li Fang Du, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf8"><p>Shuai Shao, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf9"><p>Hui Wang, is an employee of Beijing Institute of Biological Products Company Limited..</p></fn><fn fn-type="conflict" id="conf10"><p>Jun Wei Hou, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf11"><p>Ze Hua Lei, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf12"><p>Zhao Ming Liu, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf13"><p>Jin Zhang, is an employee of Beijing Institute of Biological Products Company Limited..</p></fn><fn fn-type="conflict" id="conf14"><p>Ya Nan Hou, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf15"><p>Ning Liu, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf16"><p>Fu Jie Shen, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf17"><p>Ji Guo Su, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf18"><p>Qi Ming Li, is listed as an inventor of the pending patent application for the mos-tri-RBD vaccine (Application number: 202210083654.X)..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the National Vaccine and Serum Institute (NVSI) (No. NVSI-RCD-JSDW-ER-2021238, NVSI-RCD-JSDW-ER-2022015) and conducted under the regulations for the administration of affairs concerning experimental animals of China (2017).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Figure 1 - Source Data 1, Figure 1 - Source Data 2, Figure 2 - Source Data 1, Figure 3 - Source Data 1 and Figure 4 - Source Data 1 contain the numerical data used to generate the figures. The gene sequence of the spike region of the Omicron BA.1.1 virus used in the live virus neutralization assay is provided in Appendix 1-figure 1, and the residue mutations in the Omicron BA.1.1 spike region compared to that of the prototype virus are provided in Appendix 1-figure 2.</p></sec><supplementary-material><ext-link xlink:href="elife-78633-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>